EUVIMEDEUVIMED entdecken
Crossref

Neoadjuvant Gemcitabine Plus S-1 for Resectable Pancreatic Ductal Adenocarcinoma: A Propensity Score-matched Study

Takashi Kishi, Kosuke Nakamura, Takayuki Tanaka, Kazunari Ishitobi, Shunsuke Kaji, Takahito Taniura, Takeshi Matsubara, Tetsu Yamamoto, Masaaki Hidaka

Anticancer Research · 2026

DOI: 10.21873/anticanres.18364 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Anticancer Research, 2026. Verfasst von Takashi Kishi und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of General and Digestive Surgery, Shimane University Faculty of Medicine, Shimane, Japan. Hauptthemen laut MEDLINE: Tegafur, Oxonic Acid, Deoxycytidine, Carcinoma, Pancreatic Ductal.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TegafurOxonic AcidDeoxycytidineCarcinoma, Pancreatic DuctalNeoadjuvant TherapyPancreatic NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsHumansGemcitabinePropensity ScoreDrug CombinationsFemaleAgedMaleRetrospective StudiesMiddle AgedTreatment OutcomeNeoplasm Recurrence, Local

Stichwörter der Autor:innen

Pancreatic ductal adenocarcinomagemcitabine plus S-1neoadjuvant chemotherapypropensity score matchingrelative dose intensityresectable pancreatic cancer

Substanzen

TegafurGemcitabineOxonic AcidDeoxycytidineS 1 (combination)Drug Combinations

Autor:innen und Institutionen

  • Department of General and Digestive Surgery, Shimane University Faculty of Medicine, Shimane, Japan.
  • Department of Surgery, Hamada Medical Center, Shimane, Japan.
  • Department of General and Digestive Surgery, Shimane University Faculty of Medicine, Shimane, Japan; mahidaka@med.shimane-u.ac.jp.

Zitieren

APA

Kishi, T., Nakamura, K., Tanaka, T., Ishitobi, K., Kaji, S., Taniura, T., Matsubara, T., Yamamoto, T., & Hidaka, M. (2026). Neoadjuvant Gemcitabine Plus S-1 for Resectable Pancreatic Ductal Adenocarcinoma: A Propensity Score-matched Study. Anticancer Research. https://doi.org/10.21873/anticanres.18364

Vancouver

Kishi T, Nakamura K, Tanaka T, Ishitobi K, Kaji S, Taniura T, et al. Neoadjuvant Gemcitabine Plus S-1 for Resectable Pancreatic Ductal Adenocarcinoma: A Propensity Score-matched Study. Anticancer Research. 2026. doi:10.21873/anticanres.18364

BibTeX
@article{Kishi2026,
  author = {Kishi, Takashi and Nakamura, Kosuke and Tanaka, Takayuki and Ishitobi, Kazunari and Kaji, Shunsuke and Taniura, Takahito and Matsubara, Takeshi and Yamamoto, Tetsu and Hidaka, Masaaki},
  title = {Neoadjuvant Gemcitabine Plus S-1 for Resectable Pancreatic Ductal Adenocarcinoma: A Propensity Score-matched Study},
  journal = {Anticancer Research},
  year = {2026},
  doi = {10.21873/anticanres.18364}
}
Kostenlos starten →